AbCellera Biologics Total Revenue

The latest total revenue for ABCL is $66M as of June 2026. That compares with $33M in the prior-year period — up 101.3% year over year. That is below the sector sector average of $1.3B. Investors often review this figure alongside AbCellera Biologics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ABCL's total revenue moved from $33M to $66M — a 101.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AbCellera Biologics's operating scale or balance-sheet position.

Against its sector companies, ABCL currently prints $66M for total revenue, while the sector average sits near $1.3B. That is roughly 95.0% below the sector mean. Large gaps often invite a closer look at AbCellera Biologics's growth, margins, and balance sheet.

A total revenue figure of $66M for ABCL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $1.3B. Explore the charts below for those layers of context.

After noting ABCL's total revenue ($66M), review year-over-year change from $33M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.